CME Group Inc Class A
CME: XNAS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| fbm | LOCK|HG | LOCK|!^%dPR%f |
CME Benefits From Volatile Markets Through High Trading Volume and Revenue
Business Strategy and Outlook
CME Group enjoyed favorable market conditions in 2025 as volatility across multiple asset classes drove increased trading volume, leading to strong revenue growth. CME has enjoyed a period of accelerated revenue growth since 2022, as increased interest rate uncertainty has led to a sustained increase in interest rate futures volume. We expect this tailwind to persist in 2026 before diminishing in 2027, contributing to our expectation for a deceleration in growth next year.
